Dermatologic and Infectious Diseases



Ovid: OSE Sports Medicine

Editors: Schepsis, Anthony A.; Busconi, Brian D.
Title: OSE Sports Medicine, 1st Edition
> Table of Contents > Section II – Medical Issues > 13 – Dermatologic and Infectious Diseases

13
Dermatologic and Infectious Diseases
Matthew A. Pecci
Shawn M. Ferullo
Philip Cruz
J. Herbert Stevenson
Infectious skin rashes and upper respiratory infections
are very common in athletes. The close quarters of locker rooms, shared
equipment, and skin-to-skin contact with other athletes aids in
transmission of these infections. In addition, warm, moist skin is an
ideal environment for many types of skin infections to flourish. It is
essential for sports medicine physicians to be able to recognize the
signs and symptoms of common infections. It is also important to
understand what conditions may call for temporary disqualification of
an athlete from competition.
In this chapter, we will outline and discuss some of the
most common infectious skin rashes and respiratory infections
encountered. We will discuss the course and treatment of these
illnesses. Finally, we will discuss special considerations in athletes.
DERMATOLOGIC CONDITIONS
HERPES SIMPLEX
Pathology
Herpes simplex is a DNA virus that has two distinct
types: herpes simplex 1 (HSV1) and herpes simplex 2 (HSV2). These two
types produce identical lesions and are treated the same. Therefore, it
is not essential to make the distinction between the two types at
diagnosis. Generally, HSV1 produces oral lesions such as the common
“cold sore” and

P.153

is
more common in infections obtained from athletic events. HSV2 tends to
be more common in genital infections. Herpes is spread by direct
contact with herpes lesions or by contact with fluid that contains the
virus, such as saliva or cervical secretions. The herpes virus does not
live long outside of the body, so skin-to-surface spread is uncommon.
After exposure, there is a variable incubation period of 2 to 14 days
before lesions first appear. The first time someone is infected with
herpes is considered the primary infection. The primary infection
differs from the secondary infection because the lesions generally last
longer and are preceded by prodromal symptoms—such as body aches,
fever, generalized fatigue, headaches, and tender lymph nodes—all of
which may occur a few days before the appearance of herpes lesions.
Typically, the lesions of herpes in a primary infection last 2 to 6
weeks. After the lesions heal, the virus then enters peripheral nerves
at the site of inoculation and ascends to the dorsal root ganglia,
where it remains until reactivated in a secondary infection. Herpes is
a chronic infection and can never be completely cleared from the body.

The secondary infection of herpes occurs when the latent
virus in the dorsal root ganglia is reactivated. The virus then travels
back through the peripheral nerve and causes lesions in the same area
as the previous primary infection. The herpes virus is opportunistic
and generally reactivates at times of stress or skin compromise. The
stress that may cause reactivation is variable. Common causes are upper
respiratory infections, fatigue, menstruation, or (in athletes) stress
as a result of an upcoming event or match. Also, any skin trauma, such
as a cut or scrape or even a sunburn in the area of prior infection,
may cause reactivation. The secondary infection is not preceded by
prodromal symptoms, and lesions generally last 10 to 14 days.
Diagnosis
  • The appearance of skin lesions in a
    herpes infection is typically preceded by some localized symptoms in
    the area of the lesion, including pain, burning, and tingling—all of
    which can occur 1 to 2 days before the lesion appearance.
  • The classic description of the lesions of herpes is grouped vesicles on an erythematous base (Fig. 13-1).
    • The vesicles contain clear to serosanguineous fluid and may coalesce with adjacent vesicles to form larger lesions.
    • The virus is contained within the fluid of the vesicle, and therefore these vesicles are considered contagious.
    • The skin under the vesicles tends to be erythematous but this does not extend far beyond the lesions.
    • The vesicles rupture in a few days forming shallow erosions covered by a yellowish crust.
    • These erosions will then heal in 8 to 14 days.
    • The lesions of herpes are in the
      outermost layer of the skin or the epidermis, and therefore should
      generally heal without scarring.
  • The diagnosis of herpes can often be made
    from the appearance of the lesions; but when in doubt, laboratory
    evaluation can be performed.
    • A herpes culture is most definitive for diagnosis.
    • Culture specimens can be taken from the fluid contained in the vesicles or swabbed from the base of a moist ulcer.
    • Culture yield is low once the lesions begin to dry.
    • Results of a herpes culture may take up to 1 week but can be available as soon as 1 to 2 days.
  • The other testing method is called a
    Tzanck smear, which attempts to visualize multinucleated giant cells
    (cells infected with the herpes virus).
    • The specimen for a Tzanck smear is collected by scraping the base or edges of an ulcer with a scalpel.
    • The collected specimen is then placed on a slide, fixed, and stained.
    • The benefit to this method is that a diagnosis can be made within minutes.
Figure 13-1
Herpes simplex : grouped vesicles on an erythematous base. (From
Goodheart HP. Goodheart’s Photoguide of Common Skin Disorders, 2nd ed.
Philadelphia: Lippincott Williams & Wilkins, 2003.)
Treatment
  • Herpes is a chronic, incurable disease.
  • Treatment is aimed at decreasing the time course of an outbreak, rather than curing the disease.
  • It is most effective if it is begun early in the course of an outbreak when the virus is rapidly replicating.
    • In primary infections, this is usually when the lesions first appear and are diagnosed.
    • In secondary infections, this can be
      before the lesions even appear, especially if a patient has localized
      symptoms before the outbreak.
  • At the first indication that a patient
    may be developing a secondary outbreak such as localized burning or
    tingling in the area of a prior outbreak, medication should be started.
  • There are three antiviral medications available for the treatment of herpes: acyclovir, famciclovir, and valacyclovir.
  • P.154
  • In a primary infection, begin acyclovir
    400 mg three times per day (TID) for 10 days, famciclovir 250 mg TID
    for 10 days, or valacyclovir 1,000 mg two times per day (BID) for 10
    days.
    • Topical acyclovir may also be effective in primary infections and can be applied every 4 hours for 10 days.
  • In secondary infections, begin acyclovir
    400 mg TID for 5 days, famciclovir 125 mg BID for 5 days, or
    valacyclovir 500 mg BID for 3 days.
    • Again, treatment is not curative but lessens the time to lesion healing.
  • Patients may also try a variety of drying
    agents in an attempt to hasten resolution of lesions, such as alcohol,
    bleach, or Betadine—none of which are medically recommended.
  • A patient with frequent outbreaks of
    herpes, or herpes that reoccurs predictably at times of stress, may be
    prescribed prophylactic treatment.
    • The prophylactic doses of the medications are acyclovir 400 mg BID, famciclovir 250 mg BID, or valacyclovir 500 mg QD.
Athletic Considerations
  • Herpes in the athlete is typically caused by HSV1.
  • It is called herpes gladiatorum because of its frequency in wrestlers but it can occur in athletes in any contact sport.
  • It is seen most commonly in areas of contact such as the face, neck, upper trunk, and upper extremities.
  • Because of the contagiousness of this
    disease and its incurable nature, athletes are disqualified from
    competition in any contact sport or swimming if he or she has active
    herpes lesions, even if the lesions encompass a very small area that
    can be covered with a dressing or clothing.
    • Athletes may return to competition only when the lesions are completely dry.
  • Many sports governing organizations,
    including the National Collegiate Athletic Association (NCAA), require
    that an athlete has had no new lesions for a 72-hour period before
    competition is allowed.
    • Furthermore, the NCAA also requires that
      an athlete be treated with systemic antiviral medication for at least 5
      days before the event and be taking the medication at the time of
      competition.
  • As stated previously, athletes may use a variety of topical agents in an attempt to dry the lesions as quickly as possible.
    • Athletes may also use these agents in an
      attempt to make the diagnosis difficult for the untrained clinician and
      thereby avoid disqualification.
    • If there is any question of herpes,
      however, an athlete should be disqualified from contact sports until
      further evaluation can be undertaken.
  • Because secondary herpes can occur at
    times of stress, it is very common for athletes to suffer outbreaks
    during times of important meets.
    • If this is known to occur in a given
      athlete, it may be appropriate to consider prophylactic treatment with
      antiviral medications at these times.
MOLLUSCUM CONTAGIOSUM
Pathology
Molluscum contagiosum is a pox virus that infects the
epidermis of the skin. Similar to herpes, there are two types of
molluscum viruses: MCV-1 and MCV-2. Again, it is not important to make
the distinction between the two types because they cause similar
lesions and are treated the same.
Molluscum lesions are spread by direct skin-to-skin
contact, so lesions are typically seen in areas of exposed skin such as
the face, neck, and arms. The lesions can be spread from person to
person but can also be spread to different areas of a given individual
by autoinoculation. Although not truly considered a sexually
transmitted disease, lesions can also be present in the genital area
and therefore can be spread through sexual activity.
Diagnosis
  • The lesions caused by molluscum contagiosum are papules 1 to 2 mm in size (Fig. 13-2).
    • They are typically white to skin-colored and are generally grouped in clusters.
  • One of the most characteristic traits of a molluscum contagiosum lesion is a central dimple or umbilication.
    • The umbilication is most easily seen on large lesions and is caused by a keratotic plug.
    • If this umbilication is not readily
      apparent on first inspection, it can sometimes be observed after
      treatment with liquid nitrogen.
  • Typically, the skin surrounding the
    lesions appears normal; however, individual lesions may have a
    surrounding erythematous halo.
    • This erythema may be caused by an immune reaction to the lesion and indicates it may soon clear spontaneously.
  • P.155
  • The diagnosis of molluscum is typically made by examination.
  • If the diagnosis is unclear, however, a
    Giemsa stain of the keratotic plug may reveal cells containing
    inclusion bodies that are typical of molluscum.
  • These intracytoplasmic inclusion bodies may also be seen on biopsy specimens.
Figure 13-2
Molluscum contagiosum. Characteristic dome-shaped papules, some with
central umbilication. (From Goodheart HP. Goodheart’s Photoguide of
Common Skin Disorders, 2nd ed. Philadelphia: Lippincott Williams &
Wilkins, 2003.)
Treatment
  • Molluscum lesions may undergo spontaneous resolution, but this may take up to 6 months to occur.
  • For quicker resolution, lesions can be destroyed by a variety of different methods.
  • If only a few small lesions are present, they can be removed with a curette.
  • More diffuse lesions may be treated with liquid nitrogen, electrodesiccation, or laser.
  • If the lesions are too numerous to treat
    completely, treating at least some of the lesions may stimulate the
    body to mount an immune response against the remaining lesions and
    cause spontaneous resolution.
  • It is important to remember that any of
    the previously described treatments may leave a scar or area of
    hypopigmentation, especially in dark-skinned individuals.
    • A patient should be counseled and consented as to this possibility before treatment is attempted.
Athletic Consideration
  • Because molluscum contagiosum is highly
    treatable, and does not spread systemically, athletes with lesions may
    engage in contact sports, provided the lesions can be adequately
    covered.
IMPETIGO
Pathology
Impetigo is an infection of the epidermis caused by the bacteria Staphylococcus aureus or Streptococcus pyogenes.
This infection typically occurs in areas of minor superficial breaks in
the skin. The bacteria are most prevalent in skin areas with warm,
ambient temperatures, and humidity. Therefore, outbreaks are frequent
around the nose and mouth. Also, dryness and cracking of the skin
around the lips, and trauma from shaving in this area may provide an
entrance point for the bacteria. There has also been some association
of outbreaks with poor hygiene, which may lead to a prevalence of the
bacteria on the skin. Between 20% to 40% of normal adults may have
nasal colonization of S. aureus, and about 20% may have colonization of the axilla or perineum.
Although impetigo is considered an epidermal infection,
if left untreated it can progress to a deeper skin infection such as a
cellulitis, or may even cause a systemic bacteremia. The exotoxin
produced from S. aureus may produce
detachment of the superficial layers of the epidermis causing bullous
lesions, or in certain cases widespread desquamation called staphylococcal scalded skin syndrome.
Exotoxins produced from either bacteria may cause scarlet fever. More
clinically concerning complications from systemic bacteremia such as
rheumatic fever and acute glomerulone-phritis, although not common,
have also been associated with untreated impetigo.
Diagnosis
  • The classic impetigo lesion is described as an erythematous, moist-appearing macule with a honey-colored crust (Fig. 13-3).
  • This appearance, together with a common location around the lips or nose, is generally enough to make the diagnosis.
  • There may be small lesions or larger lesions formed from confluence of these smaller ones.
  • In addition to this classic appearance,
    impetigo may appear bullous with small blister-like lesions or may
    appear dry and scaly as it is starting to heal.
  • If the diagnosis is in doubt based on
    appearance, the lesions can be swabbed for Gram stain and culture to
    confirm the presence of Staphylococcus or Streptococcus.
Treatment
  • Although the lesions of impetigo may
    resolve spontaneously, it is recommended that treatment with either
    oral or topical antibiotics be initiated at the time of diagnosis
    because of the risk of localized spread and systemic complications.
  • Very localized infections with few lesions may be treated with topical agents.
  • Mupirocin is the topical treatment of
    choice for impetigo because it is effective against even resistant
    strains of both staphylococci and streptococci.
    • Two-percent mupirocin ointment is applied to the lesions three or four times per day until the lesions have completely cleared.
  • P.156
  • It may also be beneficial for the
    infected individual to wash with an antibacterial soap such as Betadine
    or pHisoHex once per day.
  • For more widespread outbreaks, oral antibiotics are recommended.
    • Penicillin is generally not adequate for treatment because of known staphylococcal resistance.
    • Erythromycin may be inadequate because of increasing staphylococcal resistance.
  • The preferred treatment is with an
    antistaphylococcal penicillin such as cloxacillin or dicloxacillin, or
    a first-generation cephalosporin such as cephalexin.
    • The course of treatment depends on the extent of the infection, generally from 5 to 10 days.
  • For those individuals who are allergic to penicillin, azithromycin, or clarithromycin may be used.
  • For those infections that do not seem to be improving with oral antibiotics, it is recommended that a culture be performed.
  • A culture can identify the bacteria involved and its specific antibiotic sensitivities and can therefore guide treatment.
  • In addition to antibiotics, infected
    individuals should take measures to prevent further localized spread
    (such as minimizing friction or skin trauma in the infected area),
    avoid shaving the infected area, and cover lesions if possible,
    especially if the lesions are moist.
Figure 13-3
Streptococcal impetigo. Erythematous macules with moist crust. (From
Rubin E, Farber JL. Pathology, 3rd ed. Philadelphia: Lippincott
Williams & Wilkins, 1999.)
Athletic Considerations
  • Impetigo is commonly seen in the athlete.
  • It is typically spread from skin-to-skin contact and is frequently seen in sports such as wrestling.
  • The infection can also be spread from surface-to-skin contact.
    • Therefore, wrestling mats, locker rooms, or other common-use equipment may be the source of some infections.
    • It is essential that wrestling mats and
      other common-use equipment be cleaned regularly with antiseptic
      cleaners to prevent widespread outbreaks.
  • Because of the highly infectious nature
    of impetigo and the possibility of systemic complications, infected
    athletes are disqualified from contact sports until the lesions of
    impetigo are completely dried and clear of any crusting, even if the
    area can be adequately covered.
    • In most cases, this degree of clearing occurs after about 5 days of appropriate antibiotic treatment.
  • The NCAA requires an athlete have had no new lesions for 48 hours before the event before competition is allowed.
  • In widespread outbreaks among teams, careful consideration as to possible sources of the infection should be explored.
    • As previously described, common-use equipment that is not adequately cleaned may be a source.
    • Another potential source is nasal colonization of team members.
    • If this is suspected, cultures can be
      performed, or team members may be empirically treated with 2% mupirocin
      ointment applied in the nares 3 times per day for 1 week.
FOLLICULITIS
Pathology
Folliculitis is inflammation of hair follicles that can
be caused by physical irritation or, more commonly, by a bacterial
infection. Infectious folliculitis is typically caused by Staphylococcus aureus, but there is a variant of infectious folliculitis associated with the use of hot tubs called hot tub folliculitis. In hot tub folliculitis, the offending agent is often Pseudomonas aeruginosa.
Similar to impetigo, the bacteria tend to proliferate and cause
infection in warm, moist environments; thus, folliculitis is commonly
seen in areas of occlusion such as under tight clothes or in skin
folds. The lesions in hot tub folliculitis frequently develop on areas
that were covered with a bathing suit. Shaving also predisposes to hair
follicle infections, because this activity can spread bacteria and
provide breaks on the skin where bacteria may enter and cause infection.
Diagnosis
  • The typical infection of folliculitis is confined to the ostium, or superficial, portion of the hair follicle.
  • The characteristic lesions are pustules associated with hair follicles (Fig. 13-4)
    • Often, hair from the follicle can be seen extruding from the center of the pustule.
    • These infected follicles are generally grouped closely and surrounded by erythematous halos.
    • When theses pustules rupture, they appear as superficial, moist erosions, which form a crust before they heal.
  • P.157
  • Because the infection is superficial, the
    lesions often heal without scarring, but may cause postinflammatory
    pigment changes, particularly in dark-skinned individuals.
  • Even though the infection of impetigo and folliculitis both may be caused by Staphylococcus,
    in folliculitis the bacteria seem to be confined to the hair follicle,
    making risk of person-to-person transmission much less with
    folliculitis.
  • Although the infection is typically
    limited to the hair follicles, if left untreated it may progress to a
    deeper dermal infection called a “furuncle.”
    • A furuncle appears as a larger
      erythematous nodule, which can become an abscess filled with pus and
      necrotic debris. Multiple furuncles can coalesce to form a carbuncle.
    • A carbuncle is characterized by a larger area of erythema and multiple skin openings draining pus.
    • When these deeper infections occur, there is greater risk of systemic bacteremia.
  • Pustules can be unroofed with a scalpel
    or needle and cultured, which can aid in guiding treatment. This is
    especially recommended in cases that do not respond to common
    antibiotic treatment.
Figure 13-4
Folliculitis. Pustules associated with hair follicles. (From Goodheart
HP. Goodheart’s Photoguide of Common Skin Disorders, 2nd ed.
Philadelphia: Lippincott Williams & Wilkins, 2003.)
Treatment
  • Treatment is through the use of antibiotics to eradicate the infecting bacteria.
  • In localized infections, 2% mupirocin ointment can be applied 3 times per day until the lesions have cleared.
    • Washing with an antibacterial soap daily may hasten clearance and prevent spread.
  • For more widespread infections, systemic antibiotics should be used.
    • The choice of these medications is the same as with impetigo.
    • The course again varies with the severity of the infection from 5 to 10 days.
  • Infections that have spread and become a
    furuncle or abscess may need to be incised and drained, in addition to
    the use of topical antibiotics.
  • Measures to prevent spread should be
    discussed, such as avoiding shaving (until the infection has cleared)
    and avoiding the use of occlusive clothing or dressings.
    • If Pseudomonas is suspected, topical treatment with silver sulfadiazine cream may be effective.
    • More widespread infections should be treated with an oral antibiotic with antipseudomonal activity such as ciprofloxacin.
Athletic Considerations
  • Like impetigo, folliculitis is very common in the athlete due to warm, moist skin, and use of occlusive clothing.
  • Since the risk of spread is low, and
    systemic complications are rare, athletes with folliculitis may
    participate if the area can be adequately covered.
  • If the lesions have progressed to a
    draining furuncle or carbuncle, however, an athlete engaging in a
    contact sport should not be allowed to participate until the lesion is
    no longer draining.
TINEA
Pathology
Tinea refers to infection with a fungus or dermatophyte often of the Trichophyton
genus. It is classically named based on the area of the body infected.
Tinea capitis refers to an infection on the head, tinea cruris the
groin, tinea pedis the feet, and tinea corporis the body. Like many of
the bacterial infections discussed, tinea favors warm, moist
environments, so infections are commonly seen in the web space of the
toes, between the legs, and in skin fold areas. The degree of infection
seems to depend on the infected individuals cellular-based immune
response. So many individuals may carry spores on their skin but never
develop a rash, whereas others are very prone to recurrent outbreaks.
The dermatophytes infect the superficial or keratin layer of the skin,
but may infect hair and nails as well. The fungus may also live for a
variable period of time on surfaces such as shower room floors, so
surface-to-skin transmission is common.
Diagnosis
  • The skin lesions of tinea can take on
    different appearances but are classically described as well-demarcated
    patches that may have a slightly raised border.
    • These patches are often erythematous and have some superficial scaling.
    • Over time, the central erythema may clear forming an erythematous ring, hence the term ringworm is often used to describe this classic tinea rash (Fig. 13-5).
    • The lesions of tinea are generally very itchy.
  • Tinea pedis commonly infects the toe web spaces, and can cause cracked, macerated, moist appearing lesions (Fig. 13-6).

    P.158
    • Because bacteria are prevalent on the feet, this cracked skin may provide a site for bacteria entrance and superinfection.
    • This should be considered in web space infections that are very erythematous and moist.
  • Tinea capitis can cause the classic skin lesions but may also cause some overlying alopecia or hair loss.
  • Tinea cruris is very common in males and typically begins in the crural folds and extends onto the inner thigh.
    • Over time, the lesion may change from erythematous to a more red-brown color (Fig. 13-7).
    • It is uncommon for tinea cruris to infect
      the scrotum; therefore, if the scrotum is involved, one should consider
      the possibility of another type of infection such as Candida.
    • Bacteria and even repetitive friction can
      cause a similar-appearing groin rash; thus, these diagnoses should be
      considered when examining a groin rash.
  • Tinea is often diagnosed based on the location and appearance of the lesions.
  • When there is doubt, skin scrapings can be examined for the presence of the fungal organisms or hyphae.
    • The lesions are gently scraped with the edge of a glass slide or a scalpel, and these skin fragments are collected onto a slide.
    • A 10% potassium hydroxide solution is
      then applied to these fragments and a coverslip applied. The potassium
      hydroxide serves to lyse skin cells, thereby making the hyphae easier
      to visualize.
    • The slide can then be examined under low power on a microscope for the presence of hyphae.
    • Hyphae appear as branching, translucent filaments that appear to be separated into uniform segments by traversing septa.
Figure 13-5
Tinea corporis. Erythematous, scaly macule, with central clearing
(“ringworm”). (From Goodheart HP. Goodheart’s Photoguide of Common Skin
Disorders, 2nd ed. Philadelphia: Lippincott Williams & Wilkins,
2003.)
Figure 13-6
Tinea pedis (“athlete’s foot”). (From Goodheart HP. Goodheart’s
Photoguide of Common Skin Disorders, 2nd ed. Philadelphia: Lippincott
Williams & Wilkins, 2003.)
Figure 13-7
Tinea cruris (“jock itch”). (From Goodheart HP. Goodheart’s Photoguide
of Common Skin Disorders, 2nd ed. Philadelphia: Lippincott Williams
& Wilkins, 2003.)
Treatment
  • There are many different types of topical
    preparations for the treatment of a tinea infection, and all are
    available without a prescription.
  • These medications function by disrupting synthesis of a substance in the fungal cell membrane, leading to cell lysis and death.
  • Two of the major classes of topical medications are imidazoles and allylamines.
    • The imidazole class contains medications such as miconazole, clotrimazole, and ketoconazole.
    • Allylamines contain the medication terbinafine or Lamisil.
  • Both classes are effective against dermatophyte infections of the skin.
    • Some studies have shown that terbinafine
      may have a higher cure rate and more rapid response than the
      medications in the imidazole class.
  • These medications are available as creams, lotions, aerosols, or powders.
    • Generally, cream or lotion is applied to the infected area twice per day until the rash clears.
  • Tinea infections of the nails or more
    widespread infections that cannot be adequately treated with topical
    medication may need a course of oral antifungal medication.
  • There are many different oral agents available, of which the more common ones will be reviewed here.
    • Griseofulvin has been around for more than 20 years and is effective only against dermatophyte infections.
      • The typical adult dose for tinea
        infection of the skin is 500 mg/day, for anywhere from 2 to 6 weeks,
        depending on the severity of symptoms.
      • The main reported side effects are gastrointestinal upset and headaches.
    • Ketoconazole is effective against both dermatophytes and yeast.
      • The typical adult dose for tinea infection of the skin is 200 to 400 mg/day for 2 to 4 weeks.
      • One of the most concerning side effects of ketoconazole is hepatitis, which has proved fatal in several cases.
      • P.159
      • Liver enzymes should be monitored before
        starting oral treatment with ketoconazole and intermittently throughout
        the course of treatment.
    • Another oral imidazole is itraconazole, which is less hepatotoxic than ketoconazole.
      • The typical adult dose for tinea infection of the skin is 200 to 400 mg/day for 2 to 4 weeks.
    • Finally, there is an oral form of terbinafine.
      • The typical dose for tinea infections of the skin is 250 mg/day for 2 to 6 weeks.
  • In addition to using medication, it is essential to correct factors that may predispose one to developing the infection.
    • The skin should be washed daily and
      thoroughly dried before dressing, with special attention to drying skin
      fold and web space areas.
    • Talcum powder can be applied in the socks or underwear to absorb any excess moisture.
    • If clothes do get wet or sweaty, it is essential to change these as soon as possible.
    • Dermatophytes do survive on surfaces
      other than skin; therefore, in an infected individual, all clothes
      should be washed in hot (>60°C) water.
    • Any old shoes or sneakers should be discarded.
    • Shower or bathroom floors should be cleaned thoroughly with bleach.
Athletic Considerations
  • Tinea is so common in athletes that it has taken on common athletic names. Tinea pedis is commonly referred to as athlete’s foot, and tinea cruris is commonly referred to as jock itch.
  • The obvious reason for its frequency in
    athletes is that an athlete often has hot sweaty skin that favors the
    growth of dermatophytes. Also, athletes frequent areas such as locker
    rooms and common shower rooms that can harbor dermatophytes.
  • Some control measures in athletes include
    not sharing equipment, or towels; avoiding occlusive clothing; wearing
    shower shoes when showering or walking in common-use areas; and making
    sure locker rooms and shower room areas are cleaned thoroughly between
    usages.
  • Because tinea is very treatable, infected
    athletes are allowed to participate in contact sports as long as the
    rash can be adequately covered.
    • There is debate over how long an
      individual must be receiving treatment before being considered
      noninfectious, but 5 days is used as the general rule.
    • Therefore, an athlete with a more
      widespread infection, which cannot be adequately covered, should not be
      allowed to participate until he or she has been treated for at least 5
      days.
  • The NCAA requirements are slightly more
    lax, requiring only a minimum of 72 hours of topical treatment of an
    uncovered skin lesion, but 2 weeks of systemic treatment for a scalp
    lesion before competition can be allowed.
    • However, the NCAA does allow for
      decisions about competition to be made on a case-by-case basis, by
      physicians or certified athletic trainers.
  • Table 13-1 is a summary of dermatologic conditions and their treatment.
CELLULITIS, ABSCESS, AND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
Pathology
Cellulitis is a diffuse, painful inflammation of the
skin, often secondary to a local insult. The border of erythema
advances in cellulites. There are numerous etiologic bacteria that
cause this illness, including Streptococcus pyogenes, group A β-hemolytic Streptococcus, and methicillin-resistant Staphylococcus aureus
(MRSA). Cellulitis often occurs on the lower extremities or the hands,
but can occur anywhere on the dermis. An abscess is a fluctuant soft
tissue mass with overlying erythema. Abscesses are deep tissue
infections with a pocket of pus that makes the area fluctuant.
Diagnosis
  • Diagnosis is made clinically.
  • Skin temperature and color are important clinical findings.
  • It is important to monitor the infection closely.
  • Occasionally, cellulitis may progress to or indicate an underlying abscess.
  • With the new emergence of MRSA, cultures of an abscess must be considered.
  • Monitoring the infection for clinical response remains very important.
Treatment
  • The mainstay treatment of cellulitis is oral antibiotics based on underlying bacterial infection.
  • First-line antibiotics include dicloxacillin, cephalexin, and erythromycin.
  • If the infection is not responding well to oral treatment, parenteral may be necessary.
  • An abscess is treated with antibiotics, as is cellulitis.
    • It must first be incised and drained for maximal antibiotic benefits.
  • Infections secondary to
    community-acquired MRSA are usually sensitive to Bactrim among other
    antibiotics (vancomycin, clindamycin, tetracycline, and quinolones
    [some resistance already documented with quino-lones]).
Athletic Considerations
  • Community-acquired MRSA has recently
    become a more prevalent pathogen responsible for abscesses, especially
    in high school and college athletes.

    P.160
    • MRSA was first reported on sports teams
      in 1998. Other incidences on sports teams have now been more recently
      reported by the Centers for Disease Control and Prevention.
  • Guidelines for clearance do not exist.
  • If the lesions can be covered adequately and the athlete is afebrile, exclusion should not be the only option.
  • Many people are using similar criteria as is being used for herpes and impetigo in wrestling.
TABLE 13-1 SUMMARY OF DERMATOLOGIC CONDITIONS COMMONLY EXPERIENCED BY ATHLETES

Condition

Appearance

Location

Diagnosis

Treatment

Contact Sports Participation

Herpes

Grouped vesicles on an erythematous skin base

Anywhere, but most common in areas of skin-to-skin contact (i.e., face, neck, upper trunk)

By classic appearance, Tzanck smear, or culture

Incurable. Antiviral medication may decrease time of outbreak

When lesions are completely dry

Molluscum

Grouped papules, may have central umbilication

Anywhere, common on trunk and extremities

By classic appearance, or Giemsa-stain of keratotic plug

Destruction by curettage, liquid nitrogen, electrodessication, or laser

If area can be adequately covered, or after treatment

Impetigo

Erythematous macule, with moist “honey-colored” crust

Common around nose and lips

By location and appearance, or Gram stain and culture

Dicloxacillin, cephalexin, azithromycin

When lesions are completely dry

Folliculitis

Pustules associated with hair follicles

Common on extremities

By appearance, or Gram stain and culture

Dicloxacillin, cephalexin, azithromycin

If area can be adequately covered

Tinea

Well-demarcated erythematous, scaly macule. May exhibit central clearing

Anywhere, but common in warm moist environments such as the groin and toe web spaces

By appearance, or scraping, application of potassium hydroxide and visualization of hyphae under the microscope

Topical imidazoles, allylamines. Consider oral antifungal medication in widespread cases

If area can be adequately covered, or after 3 to 5 days of treatment

ACNE
Pathology
Acne is a common disorder of the skin that affects 79%
to 95% of American adolescents in the United States. Although this
problem often commences at puberty, it may persist into adulthood. Up
to 12% of females and 3% of males have persistent acne through middle
age. The increased activity of the pilosebaceous glands occur secondary
to a change in androgen levels. Acne also develops as a result of
increased sebum production, pore clogging, rapid Propionibacterium acne
production, and inflammation. This disease of the skin gives rise to
eruptions of papules and/or pustules. A papule is a small, elevated
circumscribed lesion. A pustule is a pus-filled papule. Other types of
lesions that present in acne are comedones, macules, cysts, and nodules.
Acne mechanica usually
occurs secondary to sweat, heat, friction, and occlusion from athletic
equipment or clothing. It can be seen in the presence or absence of
acne vulgaris. Common sites include the back, shoulders, and chin.
Diagnosis
  • The diagnosis of acne is made clinically.
  • The types of lesions often help determine the type and grade of acne in an athlete (Table 13-2).
  • P.161
  • Acne most frequently affects the face, but can also affect the shoulders, back, chest, upper arms, and upper legs.
TABLE 13-2 GRADING OF ACNE VULGARIS

Grade

Severity

Description

I

Mild

Open and closed comedones

II

Moderate

Erythematous papules and pustules with or without comedones, often with inflammation

III

Severe

Cystic, often with fluctuant lesions

After Savin R, Donofrio L. Aggressive acne treatment: as simple as one, two, three? Phys Sportsmed 1996;24:41.

Treatment
  • Treatment of acne involves correcting one or more of the underlying processes that results in acne formation.
  • Athletes must be told that there is no
    quick fix to acne, because it often takes 6 weeks to see the full
    benefit of each treatment.
  • Acne vulgaris responds to several treatments (Table 13-3).
  • More recent developments in acne therapy include laser therapy and newer topical retinoids (tazarotene gel).
  • Another intervention now being used with good results is photodynamic therapy with aminolevulinic acid.
  • Acne mechanica generally responds to the following:
    • Decreasing friction, occlusion, and excessive moisture (cotton under pads, use moisture transfer material).
    • Hygienic practices (immediate postpractice showering and regular washing of undergarments).
    • Topical tretinoin may be considered if acne persists despite nonpharmacologic changes.
Athletic Considerations
  • Athletes may present to the office or
    training room for acne. Advice on predisposing factors and possible
    treatment is frequently sought.
  • Equipment—including chin straps, helmets,
    sweatbands, and shoulder pads—can serve as a source of friction and
    occlusion and contribute to acne mechanica.
  • Uniforms that do not allow moisture and sweat to evaporate can result in occlusion and increased sweat production.
WARTS
Pathology
Warts are common epithelial tumors that are contagious
and are most commonly found on the hands, feet (plantar), elbows, and
knees. Warts are caused by many types of human papilloma viruses. Warts
may occur at a single location or at various locations. They can also
occur as single or multiple lesion(s). Some of these tumors can become
malignant. However, a majority of warts seen among athletes are benign.
Transmission is via contact or fomite.
TABLE 13-3 ACNE TREATMENTS

Treatment

Example

Astringents

Benzoyl peroxide

Topical antibiotics

Clindamycin solution

Keratolytics

Salicylic acid, cleansing soaps

Mechanical exfoliates

Loofah sponges

Oral antibiotics

Tetracyclines, macrolides

Retinoic acida

Topical liquid cream or gels, oral preparations

Steroid injections

Incision and drainageb

a Contraindicated during pregnancy.

b Potential for scarring exists.

Diagnosis
  • Diagnosis is made by history and physical findings.
  • The shape and distribution of various warts are characteristic in different subtypes.
  • Plantar warts are sharp, well-defined
    hyperkeratotic lesions (single or in clusters “mosaic warts”) with a
    smooth collar of thickened keratin (Fig. 13-8).
    • Often upon paring or debulking these lesions, pinpoint bleeding may occur.
    • This occurrence helps differentiate plantar warts from calluses or corns.
  • Verrucae vulgaris are raised, round, or irregular in shape, and they are sharply demarcated (Fig. 13-9).
    • These lesions usually have a rough surface and are normally from 2 to 10 mm in diameter.
    • This type frequently occurs at sites prone to trauma (e.g., hands, elbows, and knees).
    • It may also occur on the face and scalp.
Treatment
  • Verrucae vulgaris respond to numerous modalities:
    • Cryocautery with liquid nitrogen
    • 1% salicylic acid or lactic acid
    • Daily electrodesiccation with curettage
    • Recurrence rates approach 33%
  • Verrucae plantaris respond to numerous modalities:
    • 30% to 70% trichloroacetic acid
    • 40% salicylic acid
    • Taping with salicylic tape or duct tape for several days
    • P.162
    • Immunologic therapy (candida or measle intralesional injections).
Figure 13-8
Plantar wart (verrucae plantaris). Characteristic punctate bleeding is
present after paring. Note the loss of skin markings. (From Goodheart
HP. Goodheart’s Photoguide of Common Skin Disorders, 2nd ed.
Philadelphia: Lippincott Williams & Wilkins, 2003.)
Figure 13-9 Warts (verrucae vulgaris) on the knee. (Image provided by Stedman’s Medical Dictionary.)
Athletic Considerations
  • There are no set rules against participation for athletes with warts.
  • Although not necessary for participation, occlusive dressing of the wart if on an exposed area may be considered.
BLISTERS
Pathology
Blisters are intraepidermal skin lesions caused by high
moisture (perspiration or water from an outside source) in conjunction
with prolonged shearing/frictional forces. Other exacerbating factors
are poor shoe fit and/or socks that are not highly absorbent.
Treatment
  • Treatment is multifactorial.
  • If possible, leave the blister intact.
  • If it is too uncomfortable or larger than
    5 to 10 mm, then the fluid may be drained using a needle or a scalpel
    after antiseptic preparation.
  • Avoid unroofing the lesion to lower the chances of a secondary infection and decrease the degree of discomfort.
Athletic Considerations
  • Although friction blisters are certainly
    not sport-specific, they occur more frequently and are larger in tennis
    players than in many other athletes, probably because of the
    start-and-stop nature of the sport.
  • Powder may help, but many athletes use emollient lotion (lubricant).
  • Acrylic socks have also been suggested to maintain dryness.
CALLUSES AND CORNS
Pathology
Calluses and corns are the result of hyperkeratosis.
They are thickened regions of the skin that are a normal physiologic
response to multifactorial stresses. Hyperkeratosis occurs secondary to
increased mechanical stresses. Poorly fitting footwear, improper foot
mechanics, and high levels of activity are all players in the
pathogenesis of these lesions. Corns tend to be more cone-shaped and
are usually found on the dorsal and sides of the toes and feet (hard
corns; Fig. 13-10). They can also occur
between the toes (soft corn). Calluses are usually thicker and larger
than corns. They tend not to be as conical and live on the plantar
aspect of the foot (Fig. 13-11).
Diagnosis
  • This diagnosis tends to be clinical.
  • Warts are one of the few other lesions that can mimic calluses and corns.
Treatment
  • Decrease friction by avoiding improperly fitted shoes or incremental increases of activity levels.
  • After bathing, gently pumice and use lotions with lactic acid or urea to decrease the size and discomfort of calluses.
  • P.163
  • Symptomatic relief is recommended and can
    also be accomplished by various methods of padding (i.e., lambs wool,
    metatarsal pads).
  • If conservative therapy fails, there are surgical procedures that can be tried.
  • Calluses under the metatarsal heads are
    best managed conservatively, because metatarsal osteotomies have
    unpredictable results, and the callous may transfer to an adjacent
    metatarsal head.
Figure 13-10
Calluses are nonpainful, thickened patches of skin that occur at
pressure points. (From Weber J, Kelley J. Health Assessment in Nursing,
2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2003.)
Figure 13-11
Corn (clavus). The circular central translucent core resembles a kernel
of corn. (From Goodheart HP. Goodheart’s Photoguide of Common Skin
Disorders, 2nd ed. Philadelphia: Lippincott Williams & Wilkins,
2003.)
UPPER RESPIRATORY INFECTIONS
STREPTOCOCCAL PHARYNGITIS
Pathology
Sore throat is one of the most common presenting
symptoms seen in an outpatient medical practice. Both viral and
bacterial agents can lead to acute pharyngitis. It has been estimated
that 10% of the cases of sore throat that present to a clinician are
related to streptococcal infection.
Streptococcus is a class of bacteria that are
characterized as Gram-positive cocci that align in chains. The class of
streptococcus is then further subdivided into groups based on surface
proteins on the cell wall of the bacterium. Streptococcal pharyngitis
is most commonly caused by group A streptococcus but can also be less
commonly caused by group C and group G streptococci. The most important
task in the evaluation of sore throat is to identify patients infected
with group A streptococci so that they may be treated, thereby limiting
potential consequences of the infection.
Diagnosis
  • Streptococcal pharyngitis occurs most commonly in the winter and spring months.
  • It is spread by direct contact with respiratory tract secretions of a person who has the infection.
  • There is an incubation period of 2 to 4 days, followed by an abrupt onset of sore throat, fever, malaise, and headache.
  • Symptoms of generalized upper respiratory
    infection—including cough, hoarseness, laryngitis, and runny nose—are
    usually not present.
  • On physical examination, a clinician may
    find tender anterior cervical lymphadenopathy, tonsillar exudates, or
    the appearance of pus on the tonsils.
  • Because the clinical findings in
    streptococcal pharyngitis can be nonspecific, laboratory testing is
    required to definitively make the diagnosis.
  • Studies have been done looking at
    clinical predictors for strep throat to aid clinicians in making the
    preliminary diagnosis of streptococcal pharyngitis, but the predictive
    value of these factors is still unreliable.
  • The most widely used clinical predictors
    are looking for tonsillar exudates, tender anterior lymphadenopathy,
    fever >100°F, and the absence of cough.
    • If three or four of these predictors are
      present, one can be sure that the throat culture will be positive for
      streptococcus in 40% to 60% of the cases.
    • If three or four of the predictors are absent, the throat culture will be negative 80% of the time.
  • The two main forms of laboratory testing
    available to make the diagnosis of group A streptococcal pharyngitis
    are rapid antigen testing (RAT) and the gold standard of throat culture.
    • RAT kits identify streptococcal antigens
      on pharyngeal swabs and can be used in office settings to obtain an
      almost immediate result.
    • This form of testing has improved greatly
      in the last few years but still do not approach the sensitivity and
      specificity of standard throat cultures.
    • If a RAT kit is used, a positive result can be considered diagnostic and the patient may be treated.
    • If the result is negative, the test must
      be followed by a standard throat culture to ensure that it was not a
      false-negative result.
Treatment
  • Streptococcal pharyngitis is a
    self-limited infection that typically resolves on its own within 2 to 5
    days after the onset of symptoms.
  • There are still a number of reasons to
    treat the infection, including reduced severity and duration of the
    illness, reduced risk of complications from the infection, and a
    reduction in the spread of the illness to others.
    • Complications of group A streptococcal
      pharyngitis include the development of acute rheumatic fever and
      poststreptococcal glomerulonephritis.
    • The risk of developing either one of these complications is lowered greatly if the infection is properly treated.
  • Cases of group C or group G streptococcal
    pharyngitis may be treated to decrease the severity of symptoms and to
    decrease the spread of the illness, but these groups

    P.164

    are not generally associated with the development of rheumatic fever or glomerulonephritis.

  • Group A streptococcus has remained quite sensitive to penicillins.
    • The most cost-effective therapy is Penicillin VK 500 mg by mouth two times a day for 10 days.
    • In cases of penicillin allergic patients,
      either erythromycin 500 mg four times a day for 10 days, or
      azithromycin 500 mg by mouth on day 1, with 250 mg by mouth once a day
      on days 2 to 5 may be used.
Athletic Considerations
  • Athletes with streptococcal pharyngitis
    are allowed to participate in sports, provided that symptoms have
    resolved to the point that he or she feels physically able to do so.
  • Athletes who have fevers, or who are
    clinically dehydrated by examination, should be disqualified until
    these symptoms resolve or have been corrected.
  • Early detection and treatment can shorten
    the severity and duration of symptoms, allowing quicker recovery time
    and return to play.
  • In the case of team sports, it is
    important to stress hand washing and other common infection control
    measures to help decrease the spread of the infection to teammates.
  • The infected athlete should be assigned
    his or her own water bottle and other personal equipment but need not
    be quarantined from the team.
  • Table 13-4 is a summary of infectious diseases and their treatment.
VIRAL UPPER RESPIRATORY INFECTIONS
Pathology
Upper respiratory tract infections, otherwise known as
the “common cold,” are caused by a variety of viral agents and are
self-limited syndromes. Each of these viral agents cause an
indistinguishable clinical syndrome, and the identification of which
specific virus is responsible for the patient’s symptoms is irrelevant.
The most common viral agents involved in causing upper respiratory
tract infections are rhinovirus, coronavirus, parainfluenza,
respiratory syncytial virus, and adenovirus. Transmission of these
agents occurs by aerosolized droplets from the respiratory tract and
direct physical contact.
Diagnosis
  • The syndrome usually begins with mild malaise, rhinorrhea, nasal congestion, and sore throat.
  • Over the next 1 to 2 days, patients may develop laryngitis and cough.
  • Fever is unusual and, if present, is of low grade and usually does not exceed 100°F.
  • Infectivity is greatest at the time of maximal symptoms.
  • Physical examination may reveal boggy
    nasal mucosa with clear rhinorrhea, serous middle ear effusions without
    erythema, and an erythematous pharynx without exudate.
  • Lung sounds should be clear without any coarseness or focal consolidation.
Treatment
  • The mainstay of treatment of viral upper respiratory syndromes is palliative.
    • Acetaminophen or ibuprofen may be used for myalgias and low-grade fever.
    • Nasal congestion may be relieved with oral decongestants such as pseudoephedrine.
  • Patients should be sure to maintain adequate hydration and rest.
  • In some studies, supplementary vitamin C
    has been shown to decrease the duration of symptoms related to the
    common cold and may be a reasonable and safe treatment option.
Athletic Considerations
  • Similar to streptococcal pharyngitis,
    athletes with viral upper respiratory infections may participate if
    they feel physically able to do so.
  • It is important for the participating
    athlete to ensure good hydration because the illness may lead to
    dehydration from low-grade fever or poor oral intake.
  • Also, it is quite important in team
    settings that hand washing, reduced finger-to-nose contact, and
    isolation of water bottles be done to prevent spread of the infection
    to other teammates.
INFECTIOUS MONONUCLEOSIS
Pathology
Infectious mononucleosis is an illness caused by the
Epstein-Barr virus (EBV) and is characterized by the triad of fever,
tonsillar pharyngitis, and lymphadenopathy. The infection is most
common in those 10 to 19 years of age. There is also a higher incidence
of the illness in populations of young adults who are in close contact,
such as high school and college students.
EBV is a herpes virus that is primarily spread by saliva
and replicates in B lymphocytes. The incubation period of the virus is
4 to 8 weeks, and the virus can persist in the oropharynx of infected
individuals for up to 18 months after clinical recovery. Actually, most
primary EBV infections are subclinical infections and usually go
undetected.
Diagnosis
  • The typical presentation of infectious mononucleosis often begins with malaise, headache, and poor appetite.
  • It then progresses to the triad of moderate-to-high fever, pharyngitis, and lymphadenopathy.

    P.165
    • Pharyngitis is frequently accompanied by tonsillar exudate and can be confused with the appearance of streptococcal pharyngitis.
    • The characteristic lymphadenopathy is
      symmetric and typically involves the posterior cervical chain, which
      lies posterior and deep to the sternocleidomastoid muscle.
  • Other clinical findings of the syndrome
    may include severe fatigue, splenomegaly, a generalized maculopapular
    rash (which is more common with concomitant antibiotic use), hemolytic
    anemia, and thrombocytopenia.
  • Patients with suspected infectious
    mononucleosis by history and physical examination should have both a
    complete blood count with differential and heterophile antibody test
    (monospot) done to confirm the diagnosis.
    • The complete blood count will typically
      reveal a mildly elevated total white blood cell count composed of 60%
      to 70% lymphocytes, with greater than 10% being atypical.
      • Atypical lymphocytes are not specific to
        EBV infections but, when combined with the clinical picture, can be
        quite suggestive of the diagnosis.
    • Heterophile antibodies are antibodies that react to antigens from unrelated species.
      • In the case of mononucleosis, the test is performed using equine erythrocytes as the substrate.
      • The heterophile antibody test is both sensitive and specific for infectious mononucleosis.
      • A patient will develop detectable heterophile antibodies within 1 week of the onset of symptoms.
      • These antibodies will peak from 2 to 5 weeks and may persist in some patients for up to 1 year.
      • A negative heterophile antibody test may
        occur early in the course of the illness, and if the diagnosis is still
        in doubt, repeating it later may result in a positive test.
      • In a few rare instances, the heterophile antibody test will reveal a false negative.
      • In these instances, EBV-specific antibody
        testing can be obtained, which tests for antibodies directed against
        antigens on the EBV virus capsid.
TABLE 13-4 SUMMARY OF INFECTIOUS DISEASES COMMONLY EXPERIENCED BY ATHLETES

Condition

Symptoms

Exam Findings

Diagnosis

Treatment

Contact Sports Participation

Streptococcal pharyngitis

Sore throat
Fever
Malaise

Tonsillar exudates
Fever >100°F
Anterior cervical adenopathy

Rapid antigen testing kits
Throat culture

Penicillin VK
Erythromycin
Azithromycin

Full participation as long as athlete is well hydrated.

Viral upper respiratory infection

Mild malaise
Rhinorrhea
Cough
Laryngitis
Sore throat

Boggy nasal mucosa
Red pharynx
Lungs clear

Clinical based on history and PE

Supportive
Tylenol or Motrin
Fluids
Vitamin C/zinc

Full participation as long as athlete is well hydrated.

Infectious mononucleosis

Severe fatigue
Headache
Loss of appetite
Fever
Sore throat

Tonsillar exudates
Posterior cervical adenopathy
Splenomegaly
Clear rhinorrhea

CBC, with atypical lymphocytes
+ Heterophile antibodies
EBV titer

Supportive
Tylenol or Motrin
Fluids
Restriction of activity

No activity
for a minimum of 3 weeks from the onset of symptoms, or longer if
splenomegaly is present. Then a graded return to activity.

Influenza

Fever
Myalgias
Cough
Malaise
Nasal congestion
Fatigue
Quick onset of symptoms

Fever
Rhinorrhea
Red pharynx

Clinical
or
Rapid test kits
Viral culture/PCR in rare instances

Supportive
or
Amantadine
Rimantadine
Zanamivir
Oseltamivir

May return when symptomatically improved.

CBC, complete blood cell count; EBV, Epstein-Barr virus; PE, physical examination; PCR, polymerase chain reaction.

Treatment
  • Supportive care remains the mainstay in treatment of infectious mononucleosis.
  • Acetaminophen or nonsteroidal
    anti-inflammatory medication can be used for the treatment of fever,
    myalgias, and throat discomfort related to the infection.
  • Adequate rest is also important, but complete bed rest is not necessary.
  • Treatment with antiviral agents such as acyclovir has demonstrated suppression of viral shedding from infected

    P.166

    individuals but do not affect the clinical course of the illness.

  • More recently, attention has been focused on the use of corticosteroids in infectious mononucleosis.
  • Study results suggest that prednisone and
    other corticosteroids may be helpful in decreasing pharyngeal and
    lymphoid swelling but do not have any significant effect on the course
    of the infection.
Athletic Considerations
  • The two most important factors to
    consider when deciding an athlete’s return to play after infectious
    mononucleosis are spleen size and the likelihood of a decline from
    relapse of symptoms.
  • Splenic rupture accounts for the greatest risk of both morbidity and mortality in athletes with infectious mononucleosis.
  • As the spleen enlarges from the
    infiltration of lymphocytes, it becomes increasingly fragile and may
    lead to spontaneous rupture or rupture related to minor abdominal
    trauma.
  • It has been estimated that greater than 50% of patients with primary EBV infection have splenomegaly as part of the illness.
  • These changes in the spleen seem to be
    most prominent from day 4 to day 21 of the illness, with the risk of
    splenic rupture being highest at this time as well.
  • It is recommended that all athletes
    should have an absolute minimum disqualification of 21 days from the
    onset of the illness to minimize the possibility of injury to the
    spleen.
  • After day 21 of the illness, a careful physical examination should be performed focusing on assessment of the spleen size.
    • One of the major difficulties in
      determining spleen status is that the physical examination of the
      spleen is difficult and, in many cases, the spleen is enlarged even
      when it is not palpable on physical examination.
    • Abdominal ultrasound is the study of
      choice to assess spleen size in patients with infectious mononucleosis,
      but experts differ in opinion on whether an ultrasound is required
      before allowing an athlete to return to play.
    • If an athlete’s spleen status is in
      question, especially if the athlete participates in a contact sport,
      the treating physician should not hesitate to obtain an ultrasound to
      ensure that spleen size is normal.
    • At this time, however, no formal
      recommendation has been made for the use of abdominal ultrasound in the
      return-to-play decision for athletes with mononucleosis.
    • If the spleen remains enlarged by either
      physical examination or ultrasound, an athlete should be held from
      participation until splenic enlargement resolves.
  • Another question to consider when
    deciding to allow an athlete to return to play is whether the viral
    syndrome has resolved enough to prevent relapse of the symptoms of the
    illness.
    • The major concern is that too rapid of a
      return to activity may exacerbate the athlete’s symptoms lending to a
      longer time of recovery.
    • In general, all athletes should have a 3-week disqualification period.
    • If symptoms of the viral syndrome are
      resolving, and no further splenic concerns exist, the athlete may begin
      a graded return to training leading up to full participation.
INFLUENZA
Pathology
Influenza, or the flu, is an acute respiratory disease
caused by the influenza virus. The influenza virus is grouped into
three types: A, B, and C. Influenza A and influenza B are further
divided into various subtypes that cause the typical infection
associated with the flu. Influenza causes yearly epidemics from
December to March in temperate climates and can cause significant
morbidity and mortality. The virus replicates in the epithelial cells
of the respiratory tract and is spread via respiratory secretions
expelled during coughing, sneezing, or talking. The disease can spread
very quickly in close quarters such as schools, nursing home, or locker
rooms.
The incubation period for influenza is short, usually 1
to 4 days. Adults are typically infectious 1 day before symptoms appear
and, on average, 5 days into the illness. Children may be infectious
for slightly longer.
Diagnosis
  • The main challenge in diagnosis is
    differentiating the influenza virus and its symptoms from other common
    upper respiratory viruses, both of which are very prevalent during the
    winter months.
  • Some of the classic symptoms of influenza are fever (generally 100° to 104°F), myalgias, and cough.
    • These symptoms tend to be more common in influenza than in other viruses that cause colds.
  • In addition, a patient may experience
    congestion, sore throat, anorexia, and malaise similar to symptoms with
    other common winter viruses.
  • Another possible clue to differentiating influenza from other viruses is the acuity of symptoms.
    • The symptoms of influenza tend to occur
      quickly, whereas other viruses tend to have a more gradual onset with
      symptoms that occur mildly, and then progress over several days.
    • Flu symptoms also tend to resolve quickly, lasting on average 5 to 7 days; however, malaise can sometimes persist longer.
  • Mortalities related to the influenza
    occur every year typically in individuals over 65 or young children.
    From 1990 to 1999, there were approximately 36,000 deaths attributed to
    influenza.
    • The main cause of death is pneumonia,
      either from the influenza virus or as a result of a coinfection with
      another virus or bacteria.
    • P.167
    • Influenza may also worsen existing cardiac or pulmonary disease, leading to hospitalizations and sometimes death.
  • The diagnostic tests available to aid in
    the diagnosis of influenza include viral culture, serology, polymerase
    chain reaction, enzyme immunoassay, and direct immunofluorescence.
    • Many of these tests are not practical
      because the results take too long to return, and some testing methods
      only occur in specialized laboratories.
    • A viral culture is important
      epidemiologically, as it can identify the exact subtype of influenza,
      although it will not aid in treatment decisions because the results
      usually take 5 to 10 days to return.
    • There are several rapid test kits
      available that use enzyme immunoassay and immunofluorescence techniques
      and generally return results anywhere from 10 to 30 minutes. Most of
      these rapid tests are more than 70% sensitive and more than 90%
      specific.
  • One of the best ways to limit morbidity and mortality related to influenza is widespread vaccination.
    • Each year, the subtypes of influenza
      thought to be most prevalent in the given year are determined, and
      vaccines are created against these subtypes.
    • The vaccine is available as inactivated
      (killed virus), which is available via injection, and live attenuated
      virus is available via a nasal spray.
    • Typically, those at highest risk for
      complications—such as infants, the elderly, and individuals with
      chronic disease, as well as health care workers—are vaccinated as early
      as the vaccine becomes available.
    • Others can be vaccinated throughout the flu season, depending on the amount of vaccine available in a given year.
    • The main side effect of vaccination is a
      mild flu-like illness, which can be more pronounced with use of the
      live attenuated vaccine.
Treatment
  • There are medications available that may
    lessen the time course of influenza symptoms, but these need to be
    started when the virus is actively replicating usually within the first
    48 hours of symptom onset.
  • Amantadine and rimantadine have been
    available the longest; although their mechanism of action is not
    entirely understood, they are believed to inhibit an ion channel on the
    influenza A virus.
    • The major drawback is that these medications are effective only against influenza A.
    • They also may cause gastrointestinal or central nervous system side effects that may limit their use.
  • In 1999, the U.S. Food and Drug
    Administration approved the neuraminidase inhibitors zanamivir
    (Relenza) and oseltamivir (Tamiflu) for the treatment of influenza.
    • Neuraminidase is a viral glycoprotein necessary for the replication of influenza A and B.
    • The standard adult dose of oseltamivir is 75 mg twice/day for 5 days.
    • Zanamivir is administered by oral
      inhalation, and so it needs to be used with caution in those with
      existing asthma or chronic obstructive pulmonary disease, because it
      may cause bronchospasm.
      • The standard adult dose of zanamivir is 10 mg delivered via an inhalation device twice per day for 5 days.
    • The benefit of these medications is that they are effective against both influenza A and B. The main drawback is the cost.
    • In addition to their use for treatment of
      influenza, amantadine, rimantadine, and oseltamivir have been approved
      for chemoprophylaxis of close contacts of individuals diagnosed with
      influenza.
Athletic Considerations
  • Outbreaks of influenza can spread quickly
    among teams, so it is important to make the diagnosis early so that the
    infected individual may be removed from contact with teammates.
  • Infected individuals should avoid contact with others for 5 days.
    • However, if treatment is begun within the first 48 hours of symptom onset, the infectious period is likely lessened.
  • There are no good data on the duration of the infectious period in a treated individual, but a general rule is 3 days.
  • Unvaccinated, close contacts of individuals who are diagnosed with influenza may undergo chemoprophylaxis to prevent infection.
  • Infected individuals may return to competition when they are symptomatically improved, which may take 3 to 10 days.
  • Again, the malaise from influenza may last longer than 1 week and may be a limiting factor in return to activity.
    • An individual should not be allowed to return if they are still febrile or clinically dehydrated.
  • If the supplies of vaccine allow,
    vaccinating teams who are active in the winter months early in the flu
    season is the ideal way to prevent team epidemics.
SUGGESTED READING
Aronson, MD. Infectious mononucleosis in adults and adolescents. Up To Date Online. Accessed October 25, 2004.
Bartlett JG. Approach to acute pharyngitis in adults. Up To Date Online. Accessed October 25, 2004.
Bergfeld WF. Dermatologic problems in athletes. Clin Sports Med 1982;1:419-430.
Bisno
AL, Peter GS, Kaplan EL. Diagnosis of strep throat in adults: are
clinical criteria really good enough? Clin Infect Dis 2002;35:126.
Bisno AL. Acute pharyngitis. N Engl J Med 2001;344:205.
Brandfonbrener A, Epstein A, Wu S, et al. Corticosteroid therapy in Epstein-Barr virus infection. Arch Intern Med 1986;146:337.
Burroughs KE. Athletes resuming activity after infectious mononucleosis. Arch Fam Med 2000;9:1122.
Conklin RJ. Common cutaneous disorders in athletes. Sports Med 1990;9:100-117.

P.168
Cooper
RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate
antibiotic use for acute pharyngitis in adults: background. Ann Intern
Med 2001;134:509.
Dienst
WL Jr, Dightman L, Dworkin MS, et al. Pinning down skin infections:
diagnosis, treatment, and prevention in wrestlers. Phys Sportsmed
1997;25.
Dommerby
H, Stangerup SE, Stangerup M, et al. Hepatosplenomegaly in infectious
mononucleosis, assessed by ultrasonic scanning. Laryngol Otol
1986;100:573-579.
Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Phys 2004;70:1279.
Eiland G, Ridley D. Dermatological problems in the athlete. J Orthop Sports Phys Ther 1996;23:388-402.
Fitzpatrick TB, Johnson RA, Wolff K, et al. Color Atlas and Synopsis of Clinical Dermatology. New York: McGraw-Hill, 1997.
Friedman ND, Sexton DJ. The common cold in adults. Up To Date Online. Accessed November 12, 2004.
Habif T. Clinical Dermatology. St. Louis: Mosby, 1996.
Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza. MMWR 2004;53(RR06):1-40.
Karlowski
TR, Chalmers TC, Frenkel LD, et al. Ascorbic acid for the common cold,
a prophylactic and therapeutic trial. JAMA 1998; 231:1038.
Kirkpatrick GL. The common cold. Primary Care 1996;23:657.
Landry GL, Chang CJ. Herpes and tinea in wrestling. Phys Sportsmed 2004;32:43-44.
Levy JA. Common bacterial dermatoses. Phys Sportsmed 2004;32: 33-39.
MacKnight JM. Infectious mononucleosis. Phys Sportsmed 2002;30: 27-31.
Montaldo NJ. An office-based approach to influenza: clinical diagnosis and laboratory testing. Am Fam Physician 2003;67:111-118.
Montaldo NJ, Gum KD, Ashley JV. Updated treatment for influenza A and B. Am Fam Physician 2000;62:2467-2476.
Snow
V, Mottur-Dilson C, Cooper RJ, et al. Principles of appropriate
antibiotic use for acute pharyngitis in adults. Ann Intern Med 2001;
134:506.
Srivastava
KP, Quinlan EC, Casey TV. Spontaneous rupture of the spleen secondary
to infectious mononucleosis. Intern Surg 1972; 57:171-173.
Tynell
E, Aurelius E, Brandell C, et al. Acyclovir and prednisolone treatment
of acute infectious mononucleosis: a multicenter, double blind,
placebo-controlled study. J Infect Dis 1996;174:324.
York WH. Spontaneous rupture of the spleen: report of a case secondary to infectious mononucleosis. JAMA 1962;179:170-171.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More